March 08, 2026 — 82 articles reviewed
This cycle was dominated by a surge of coverage around cannabis compounds and fatty liver disease, alongside consistent warnings about adolescent psychiatric risk and promising advances in cannabinoid drug delivery. Clinicians also saw emerging signals that GLP-1 agonists may reduce substance use disorder risk, plus ongoing regulatory battles over THC potency, drug testing, and occupational access.
🧬 CBD, CBG, and Fatty Liver Disease: One Study, Major Coverage
A single preclinical study from Israeli researchers led by Prof. Joseph Tam received extensive media coverage this cycle, demonstrating that CBD and CBG reduce hepatic lipid accumulation and improve metabolic markers in laboratory models of nonalcoholic fatty liver disease. This matters because NAFLD affects roughly 25% of adults globally and currently has no FDA-approved pharmacological treatment beyond lifestyle modification. The cannabinoid compounds appear to work through endocannabinoid receptor pathways, with CB2 activation showing anti-inflammatory and antifibrotic benefits in hepatic tissue. Clinicians should recognize this as encouraging but firmly preclinical evidence, and patients with fatty liver disease should continue standard care while we await rigorous human trials. The therapeutic gap in NAFLD management makes this research worth tracking closely, but recommending cannabis products for liver disease today would be premature.
- #78Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
- #78Study reveals cannabis compounds reduce threat of fatty liver disease | Health
- #75Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …
- #75Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health
- #75Study reveals cannabis compounds reduce threat of fatty liver disease | Health – News-Topic
- #72Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
- #72Cannabis Compounds Exhibit Potential in Combatting Fatty Liver Disease
- #72Study reveals cannabis compounds reduce threat of fatty liver disease | Health – WFMZ.com
🧠 Adolescent Cannabis Use and Psychiatric Risk: The Evidence Keeps Building
A longitudinal study finding that adolescent cannabis use approximately doubles the risk of developing psychotic and bipolar disorders by young adulthood received broad coverage this cycle, reinforcing what the neurodevelopmental literature has been showing for years. The vulnerability window during prefrontal cortex and dopaminergic system maturation makes teenage exposure fundamentally different from adult use, and this risk appears particularly elevated in youth with family histories of serious mental illness. Separately, Children’s National Hospital reported treating children as young as 11 for cannabis use disorder, with ease of access cited as a primary driver. Clinicians should screen for cannabis use at every adolescent visit, counsel families directly about psychiatric risk, and recognize that early-onset use often signals untreated anxiety, ADHD, or trauma rather than isolated substance experimentation. Prevention messaging must be specific and evidence-based rather than relying on generic “just say no” approaches that adolescents routinely dismiss.
- #78Study: Adolescent cannabis use linked to doubling risk of psychotic and bipolar disorders
- #72Kids as young as 11 being treated for cannabis use disorder, Children’s National Hospital says
- #65Youth and cannabis: What’s the risk? – The Lewiston Tribune
💊 Cannabinoid Delivery Science: Solving the Bioavailability Problem
A comprehensive review published in PubMed on oral mucosal cannabinoid delivery systems received repeated coverage, addressing the fundamental pharmacokinetic barriers that have plagued cannabis medicine: poor water solubility, hepatic first-pass metabolism, and wildly inconsistent bioavailability. Sublingual, buccal, and oromucosal formulations using lipid-based systems, nanoparticles, and mucoadhesive polymers can bypass first-pass metabolism and deliver more predictable plasma levels. This is not an academic exercise; inconsistent dosing is the primary reason many patients either fail to achieve therapeutic benefit or experience unexpected adverse effects from oral cannabis products. For conditions requiring dosing precision like epilepsy and breakthrough pain, these delivery advances could transform cannabis from a trial-and-error intervention into a reproducible clinical tool. Clinicians should understand that a clinical trial this cycle also demonstrated sublingual cannabis extracts significantly reducing myofascial pain in temporomandibular disorder, validating the mucosal route in practice.
- #78Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
- #78Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
👴 Older Adults: Cognitive Safety Reassurance, Plus Anxiety Relief
A longitudinal study examining lifetime cannabis use in older adults found no association between cannabis exposure and cognitive decline or dementia risk, a finding that received consistent coverage and challenges long-standing clinical assumptions. This does not mean cannabis is cognitively protective, but it does remove a major barrier to discussing cannabinoid therapy for chronic pain, insomnia, and anxiety in geriatric populations. Separately, a study on CBD-dominant products demonstrated significant anxiety relief in older adults, suggesting that low-THC formulations may offer therapeutic benefit without the cognitive or psychiatric concerns associated with high-THC products. Clinicians can now counsel older patients more confidently that cannabis use does not appear to accelerate cognitive aging, while still monitoring for acute effects, fall risk, and drug interactions with common geriatric medications. The practical shift here is from blanket discouragement to individualized risk-benefit assessment.
- #78Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults
- #78Cannabis use not linked to cognitive decline or dementia in older adults, study finds – leafie
- #75Study: Cannabis use among older adults does not accelerate mental decline
- #75Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
⚖️ Regulation, Access, and the Policy Patchwork
This cycle saw significant legislative and regulatory activity across multiple states: Alabama preparing for spring 2026 dispensary launches, West Virginia allocating $34 million in unspent cannabis revenue, Tennessee debating medical marijuana’s future, Oregon defeating THC potency caps on edibles, and Maryland delaying a vote on firefighter medical cannabis access. Ohio issued a gummy recall over missing THC labeling symbols, while federal agencies warned about medical cannabis detection in drug tests creating legal jeopardy for compliant patients. Georgia’s HB 496 would protect medical cannabis patients from arrest based on marijuana odor alone, addressing a real clinical barrier to treatment adherence. The hemp beverage market continues to outpace FDA oversight, with cease-and-desist letters highlighting the gap between commercial claims and clinical evidence. Clinicians must stay current with their jurisdiction’s specific regulatory landscape because the rules directly affect what they can recommend, what patients can safely access, and whether legal protections exist for medically authorized use.
- #75Smoking Cannabis May Reduce Alcohol Cravings, New Study Finds – Food & Wine
- #72House Bill 496 in Georgia would stop police from stopping, searching, or arresting … – Instagram
- #72Feds warn about medical cannabis & hemp in drug tests (Newsletter: March 6, 2026)
- #55West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …
- #55Oregon Bill To Ban Marijuana Edibles With More Than 10 Milligrams Of THC Fails
- #55Maryland Senate Delays Vote on Bill Allowing Firefighters to Use Medical Cannabis Off-Duty
- #55From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
- #45Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
- #45The Wait is Over: Medical Cannabis set to roll out in April | WKRG.com
- #45Bill allocating medical cannabis funds passes House – Mountain State Spotlight
- #45Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
- #45Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo
- #45Ohio Department of Commerce recalls certain marijuana gummies lacking THC symbol … – Facebook
The science is advancing faster than the policy, and this cycle proves it: we have compelling preclinical data on liver disease, reassuring cognitive safety data in older adults, and real delivery technology breakthroughs, all while patients navigate a regulatory landscape that still punishes them for following their physician’s recommendations. Clinicians who stay current with this evidence will be the ones who can actually help their patients make informed decisions rather than guessing in the dark.
Digest-Level Clinical Commentary
# Clinical Reflection The emerging evidence linking cannabis compounds to fatty liver disease trajectories, particularly in the context of rising GLP-1 agonist use among patients with metabolic syndrome, suggests we need to refine our patient stratification protocols and drug interaction assessments in cannabis medicine practice. Given the persistent adolescent safety signals and potential metabolic interactions with increasingly prevalent obesity medications, I’m reconsidering my baseline screening approach to include liver function assessment and metabolic risk profiling before recommending cannabis therapeutics. This convergence of data points toward a more nuanced, personalized medicine framework rather than the population-level recommendations that have historically guided our field.
# Clinical Perspective Recent literature highlights a growing body of evidence examining cannabis’ metabolic effects, particularly regarding hepatic steatosis, which warrants closer monitoring in patient populations with existing metabolic risk factors. Concurrently, emerging data on GLP-1 agonists’ potential role in substance use disorder reduction represents an intriguing mechanistic avenue that may inform future prevention and treatment strategies. These trends underscore the importance of integrating cannabis exposure assessment into standard metabolic evaluations while maintaining vigilance around adolescent use given developmental considerations.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: